<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34641339</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-3049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecules (Basel, Switzerland)</Title>
          <ISOAbbreviation>Molecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5795</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules26195795</ELocationID>
        <Abstract>
          <AbstractText>The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Imran</LastName>
            <ForeName>Mohd</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-6064-1040</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumar Arora</LastName>
            <ForeName>Mandeep</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asdaq</LastName>
            <ForeName>Syed Mohammed Basheeruddin</ForeName>
            <Initials>SMB</Initials>
            <Identifier Source="ORCID">0000-0003-1533-9667</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khan</LastName>
            <ForeName>Shah Alam</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0002-0729-3403</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, National University of Science and Technology, Muscat 130, Oman.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alaqel</LastName>
            <ForeName>Saleh I</ForeName>
            <Initials>SI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshammari</LastName>
            <ForeName>Mohammed Kanan</ForeName>
            <Initials>MK</Initials>
            <Identifier Source="ORCID">0000-0001-6687-0461</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Care, Rafha Central Hospital, North Zone, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshehri</LastName>
            <ForeName>Mohammed M</ForeName>
            <Initials>MM</Initials>
            <Identifier Source="ORCID">0000-0002-2041-4695</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Care Department, Ministry of National Guard-Health Affairs, Riyadh 11426, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alshrari</LastName>
            <ForeName>Ahmed Subeh</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Laboratory Technology Department, Faculty of Applied Medical Science, Northern Border University, Arar 91431, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mateq Ali</LastName>
            <ForeName>Alreshidi</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3621-6738</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Laboratory Sciences, Sulaiman ALrajhi University, Albukairah 51941, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Shammeri</LastName>
            <ForeName>Ahmed Muteb</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Affairs, Dammam Health Network, Eastern Health Cluster, Dammam 31146, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alhazmi</LastName>
            <ForeName>Bushra Dhuhayyan</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harshan</LastName>
            <ForeName>Aishah Ali</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Care, Northern Area Armed Forces Hospital, King Khalid Military City Hospital, Hafr Al-Batin 31991, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alam</LastName>
            <ForeName>Md Tauquir</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abida</LastName>
            <Identifier Source="ORCID">0000-0001-6186-461X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Molecules</MedlineTA>
        <NlmUniqueID>100964009</NlmUniqueID>
        <ISSNLinking>1420-3049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.49</RegistryNumber>
          <NameOfSubstance UI="D012194">RNA-Directed DNA Polymerase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012194" MajorTopicYN="N">RNA-Directed DNA Polymerase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19</Keyword>
        <Keyword MajorTopicYN="N">EIDD-1931</Keyword>
        <Keyword MajorTopicYN="N">EIDD-2801</Keyword>
        <Keyword MajorTopicYN="N">MK-4482</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">patents</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
          <Hour>1</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34641339</ArticleId>
        <ArticleId IdType="pmc">PMC8510125</ArticleId>
        <ArticleId IdType="doi">10.3390/molecules26195795</ArticleId>
        <ArticleId IdType="pii">molecules26195795</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Rufaida M.T., Kedwai I., Ahsan F., Shamim A., Shariq M., Parveen S. A dossier on COVID-19 chronicle. J. Basic Clin. Physiol. Pharmacol. 2021 doi: 10.1515/jbcpp-2020-0511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/jbcpp-2020-0511</ArticleId>
            <ArticleId IdType="pubmed">34280963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> [(accessed on 16 August 2021)].  Available online:  https://covid19.who.int.</Citation>
        </Reference>
        <Reference>
          <Citation>Couvreur P., Louvard D. COVID-19 and drugs: Pathophysiology and therapeutic approaches. Comptes Rendus Biol. 2021;344:27–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34213847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falzone L., Gattuso G., Tsatsakis A., Spandidos D.A., Libra M. Current and innovative methods for the diagnosis of COVID-19 infection (Review) Int. J. Mol. Med. 2021;47:1–23. doi: 10.3892/ijmm.2021.4933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2021.4933</ArticleId>
            <ArticleId IdType="pmc">PMC8043662</ArticleId>
            <ArticleId IdType="pubmed">33846767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bestetti R.B., Furlan-Daniel R., Silva V.M.R. Pharmacological treatment of patients with mild to moderate COVID-19: A comprehensive review. Int. J. Environ. Res. Public Health. 2021;18:7212.  doi: 10.3390/ijerph18137212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph18137212</ArticleId>
            <ArticleId IdType="pmc">PMC8297311</ArticleId>
            <ArticleId IdType="pubmed">34281149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das K., Pingali M.S., Paital B., Panda F., Pati S.G., Singh A., Varadwaj P.K., Samanta S.K. A detailed review of the outbreak of COVID-19. Front. Biosci. (Landmark Ed.) 2021;26:149–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34162043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B., Liu M., Huang C. Current diagnostic and therapeutic strategies for COVID-19. J. Pharm Analysis. 2021;11:129–137. doi: 10.1016/j.jpha.2020.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpha.2020.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC7832669</ArticleId>
            <ArticleId IdType="pubmed">33520327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imran M., Alshrari A.S., Asdaq S.M.B.,  Abida. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review. J. Infect. Public Health. 2021;14:1075–1086. doi: 10.1016/j.jiph.2021.06.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2021.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC8236076</ArticleId>
            <ArticleId IdType="pubmed">34243049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghasemnejad-Berenji M., Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug Res. (Stuttg) 2021;71:166–170. doi: 10.1055/a-1296-7935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/a-1296-7935</ArticleId>
            <ArticleId IdType="pmc">PMC8043595</ArticleId>
            <ArticleId IdType="pubmed">33176367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christie A., Mbaeyi S.A., Walensky R.P. CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. JAMA. 2021;325:1501–1502. doi: 10.1001/jama.2021.4367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.4367</ArticleId>
            <ArticleId IdType="pubmed">33688914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei M., Tan X. Current Strategies of Antiviral Drug Discovery for COVID-19. Front. Mol. Biosci. 2021;8:671263. doi: 10.3389/fmolb.2021.671263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmolb.2021.671263</ArticleId>
            <ArticleId IdType="pmc">PMC8155633</ArticleId>
            <ArticleId IdType="pubmed">34055887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan S.A., Al-Balushi K. Combating COVID-19: The role of drug repurposing and medicinal plants. J. Infect. Public Health. 2021;14:495–503. doi: 10.1016/j.jiph.2020.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2020.10.012</ArticleId>
            <ArticleId IdType="pmc">PMC7590838</ArticleId>
            <ArticleId IdType="pubmed">33743371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., et al.  Drug repurposing: Progress.; challenges and recommendations. Nat. Rev. Drug Discov. 2019;18:41–58. doi: 10.1038/nrd.2018.168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId>
            <ArticleId IdType="pubmed">30310233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Anirudhan V., Du R., Cui Q., Rong L. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J. Med. Virol. 2021;93:300–310. doi: 10.1002/jmv.26264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26264</ArticleId>
            <ArticleId IdType="pubmed">32633831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vicenti I., Zazzi M., Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin. Ther. Pat. 2021;31:325–337. doi: 10.1080/13543776.2021.1880568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543776.2021.1880568</ArticleId>
            <ArticleId IdType="pmc">PMC7938656</ArticleId>
            <ArticleId IdType="pubmed">33475441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu B., Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc. Natl. Acad. Sci. USA. 2016;113:E4005-14. doi: 10.1073/pnas.1602591113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1602591113</ArticleId>
            <ArticleId IdType="pmc">PMC4948327</ArticleId>
            <ArticleId IdType="pubmed">27339134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.X., et al.  Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020;382:2327–2336. doi: 10.1056/NEJMoa2007016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2007016</ArticleId>
            <ArticleId IdType="pmc">PMC7169476</ArticleId>
            <ArticleId IdType="pubmed">32275812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., et al.  Remdesivir in adults with severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId>
            <ArticleId IdType="pmc">PMC7190303</ArticleId>
            <ArticleId IdType="pubmed">32423584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., Liao X., Gu Y., Cai Q., Yang Y., et al.  Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering. 2020;6:1192–1198. doi: 10.1016/j.eng.2020.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eng.2020.03.007</ArticleId>
            <ArticleId IdType="pmc">PMC7185795</ArticleId>
            <ArticleId IdType="pubmed">32346491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer W., Eron J., Holman W., Cohen M.S., Fang L., Szewczyk L.J., Sheahan T.P., Baric R., Mollan K.R., Wolfe C.R., et al.  Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv. 2021 doi: 10.1101/2021.06.17.21258639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.17.21258639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N.C.J.E., Morin M.J., Szewczyk L.J., Painter G.R. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob. Agents Chemother. 2021;65:e02428-20. doi: 10.1128/AAC.02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02428-20</ArticleId>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al.  Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>From the American Association of Neurological Surgeons (AANS) American Society of Neuroradiology (ASNR) Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Canadian Interventional Radiology Association (CIRA) Congress of Neurological Surgeons (CNS) European Society of Minimally Invasive Neurological Therapy (ESMINT) European Society of Neuroradiology (ESNR) European Stroke Organization (ESO) Society for Cardiovascular Angiography and Interventions (SCAI) Society of Interventional Radiology (SIR) et al.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int. J. Stroke. 2018;13:612–632. doi: 10.1016/j.jvir.2017.11.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvir.2017.11.026</ArticleId>
            <ArticleId IdType="pubmed">29786478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., et al.  Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrob. Agents Chemother. 2018;62:e00766-18. doi: 10.1128/AAC.00766-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00766-18</ArticleId>
            <ArticleId IdType="pmc">PMC6105843</ArticleId>
            <ArticleId IdType="pubmed">29891600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Natchus M.G., Cohen O., Holman W., Painter W.P. Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19. Curr. Opin. Virol. 2021;50:17–22. doi: 10.1016/j.coviro.2021.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coviro.2021.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC8277160</ArticleId>
            <ArticleId IdType="pubmed">34271264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Yang L. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. Front. Pharmacol. 2020;11:1013. doi: 10.3389/fphar.2020.01013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.01013</ArticleId>
            <ArticleId IdType="pmc">PMC7343773</ArticleId>
            <ArticleId IdType="pubmed">32714193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schäfer A., Dinnon K.H., 3rd, Stevens L.J., et al.  An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutic MK-4482/EIDD-2801 Blocks SARS-CoV-2 Transmission in Ferrets. Res. Sq. 2020 doi: 10.21203/rs.3.rs-89433/v1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21203/rs.3.rs-89433/v1</ArticleId>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Bluemling G.R., Natchus M.R., Guthrie D.B. N4-hydroxycytidine and Derivatives and Anti-viral Uses Related Thereto. 2020276219A1. U.S. Patent. 2020 September 3;</Citation>
        </Reference>
        <Reference>
          <Citation>Xuchun Z., Yiping Z., Chenchen F. Molnupiravir Crystal form A and Preparation Method Thereof. 112778387A. CN Patent. 2021 May 11;</Citation>
        </Reference>
        <Reference>
          <Citation>Jian C., Changquan Y., Chenchen F. Preparation Method of 4-oxime-5′-(2-methylpropionyl) Uridine. 112552288A. CN Patent. 2021 March 26;</Citation>
        </Reference>
        <Reference>
          <Citation>Xuchun Z., Yiping Z., Chenchen F. Preparation Method of Antiviral Drug Molnbupiravir. 112608357A. CN Patent. 2021 April 6;</Citation>
        </Reference>
        <Reference>
          <Citation>Prasad M.K., Rao M.A. Process for the Preparation of Molnupiravir. 202141018775A. IN Patent. 2021 May 7;</Citation>
        </Reference>
        <Reference>
          <Citation>Akira A., Kisaburo U., Tatsuro Y. Carbamoyloxycytidines. 48000578A. JP Patent. 1973 January 6;</Citation>
        </Reference>
        <Reference>
          <Citation>Sledziewska E., Janion C. Mutagenic Specificity of N4-hydroxycytidine. Mutat. Res. 1980;70:11–16. doi: 10.1016/0027-5107(80)90053-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0027-5107(80)90053-6</ArticleId>
            <ArticleId IdType="pubmed">7366595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schinazi R.F., Amblard F., Cox B.D., Bassit L., Zhou L., Gavegnano C. Antiviral Agents for Treating Zika and Dengue Virus Infections. 2017165489A1. WO Patent. 2017 September 28;</Citation>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Guthrie D.B., Bluemling G.R., Natchus M.R. N4-hydroxycytidine and Derivatives and Anti-viral Uses Related Thereto. 10874683B2. U.S. Patent. 2020 December 29;</Citation>
        </Reference>
        <Reference>
          <Citation>Liotta D.C., Painter G.R., Bluemling G.R., Rosa A.D.L. Nucleotide and Nucleoside Therapeutics Compositions and Uses Related Thereto. 2016145142A1. WO Patent. 2016 September 15;</Citation>
        </Reference>
        <Reference>
          <Citation>Bluemling G.R., Guthrie D.B., Natchus M.G., Painter G.R. N4-hydroxycytidine and Derivatives and Anti-viral Uses Related Thereto. 2015370004B2. AU Patent. 2021 March 11;</Citation>
        </Reference>
        <Reference>
          <Citation>Liotta D.C., Painter G.R., Bluemling G.R., Rosa A.D.L. Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto. 10149859B2. U.S. Patent. 2018 December 11;</Citation>
        </Reference>
        <Reference>
          <Citation>Loakes D., Brown D.M., Negishi K., Moriyama K., Balzarini J. Inhibition of Viruses. 7049303B2. U.S. Patent. 2006 May 23;</Citation>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Perryman D., Bluemling G.R. 4′-halogen Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto. 2019173602A1. WO Patent. 2019 September 12;</Citation>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Perryman D., Bluemling G.R. 4′-halogen Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto. 2021137913A2. WO Patent. 2021 July 8;</Citation>
        </Reference>
        <Reference>
          <Citation>Nandi I., Mukherjee T., Kumar D., Jain A., Soni P., Mistry G.N., Jaiswal N. Transmucosal Pharmaceutical Compositions of Antiviral Drugs. 202114023358. IN Patent. 2021 June 18;</Citation>
        </Reference>
        <Reference>
          <Citation>Lederman S. Anti-cd154 Antibodies and Uses Thereof. 2021001458A1. WO Patent. 2021 January 7;</Citation>
        </Reference>
        <Reference>
          <Citation>Lederman S., Daugherty B. Modified Tff2 Polypeptides. 2021038296A2. WO Patent. 2021 March 4;</Citation>
        </Reference>
        <Reference>
          <Citation>Li S., Yuan L. Substituted N4-hydroxycytidine Derivatives and Prodrugs Thereof for Use in Anti-novel Coronavirus Therapy. 111548384A. CN Patent. 2021 April 27;</Citation>
        </Reference>
        <Reference>
          <Citation>Qingyan B.O., Yuyan J.I.N., Tyagi G., Zhu Y. Method of Treating Virus Infection Using a tlr7 Agonist. 2021130195A1. WO Patent. 2021 July 1;</Citation>
        </Reference>
        <Reference>
          <Citation>Yuanchao X., Gengfu X., Yang H., Lei Z., Hualiang J., Jingshan S. Application of Nucleoside Analogue or Combination Preparation Containing Nucleoside Analogue in Resisting Virus. 112778310A. CN Patent. 2021 May 11;</Citation>
        </Reference>
        <Reference>
          <Citation>Schinazi R.F., Zandi K., Amblard F. Peptidomimetics for the Treatment of Coronavirus and Picornavirus Infections. 2021008150A1. U.S. Patent. 2021 January 14;</Citation>
        </Reference>
        <Reference>
          <Citation>Cho A., Link J.O., Xu J. 2-Imino-5-Oxo-Imidazolidine Inhibitors of HIV Protease. 2020214716A1. WO Patent. 2020 October 22;</Citation>
        </Reference>
        <Reference>
          <Citation>Peyman G.A. Method of Treating, Reducing, or Alleviating a Medical Condition in A Patient. 20210228619A1. U.S. Patent. 2021 July 29;</Citation>
        </Reference>
        <Reference>
          <Citation>Cihlar T., Osinusi A., Porter D.L. Methods for Treating Sars Cov-2 Infections. 2021154687A1. WO Patent. 2021 August 5;</Citation>
        </Reference>
        <Reference>
          <Citation>Chaudhuri R.K., Randhawa M. Multi-Targeted Compositions for Mitigating Acute Respiratory Distress Syndrome. 20210236529A1. U.S. Patent. 2021 August 5;</Citation>
        </Reference>
        <Reference>
          <Citation>Jordan P.C., Stevens S.K., Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir. Chem. Chemother. 2018;26:2040206618764483. doi: 10.1177/2040206618764483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040206618764483</ArticleId>
            <ArticleId IdType="pmc">PMC5890544</ArticleId>
            <ArticleId IdType="pubmed">29562753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H.S., Höbartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021 doi: 10.1038/s41594-021-00651-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId>
            <ArticleId IdType="pmc">PMC8437801</ArticleId>
            <ArticleId IdType="pubmed">34381216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., Sheahan T.P., Baric R.S., Heise M.T., Swanstrom R. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J. Infect. Dis. 2021;224:415–419. doi: 10.1093/infdis/jiab247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId>
            <ArticleId IdType="pmc">PMC8136050</ArticleId>
            <ArticleId IdType="pubmed">33961695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiremath C.N. Abbreviated Profile of Drugs (APOD): Modeling drug safety profiles to prioritize investigational COVID-19 treatments. Heliyon. 2021;7:e07666. doi: 10.1016/j.heliyon.2021.e07666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.heliyon.2021.e07666</ArticleId>
            <ArticleId IdType="pmc">PMC8317482</ArticleId>
            <ArticleId IdType="pubmed">34337170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imran M., Asdaq S.M.B., Khan S.A., Unnikrishnan M.D., Alamri A.S., Alsanie W.F., Alhomrani M., Mohzari Y., Alrashed A., AlMotairi M., et al.  Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals. 2021;14:710.  doi: 10.3390/ph14080710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph14080710</ArticleId>
            <ArticleId IdType="pmc">PMC8400070</ArticleId>
            <ArticleId IdType="pubmed">34451807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paymode D.J., Vasudevan N., Ahmad S., Kadam A.L., Cardoso F.S.P., Burns J.M., Cook D.W., Stringham R.W., Snead D.R. Toward a practical, two-step process for molnupiravir: Direct hydroxamination of cytidine followed by selective esterification. Org. Process. Res. Dev. 2021 doi: 10.1021/acs.oprd.1c00033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.oprd.1c00033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes D.T. Quest for a cure: Potential small-molecule treatments for COVID-19, Part 2. Org. Process. Res. Dev. 2021;25:1089–1111. doi: 10.1021/acs.oprd.1c00100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.oprd.1c00100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datla A., Nagre P., Tamore J., Prabhu M.S., Trivikram S., Kadam S.V., Degaonkar G.S., Muralidharan K., Rupraj N. Scalable Two Step Synthesis of Molnupiravir. 202121014827A. IN Patent. 2021 August 20;</Citation>
        </Reference>
        <Reference>
          <Citation>Datla A., Nagre P., Tamore J., Prabhu M.S., Trivikram S. Chemo-Enzymatic Process for Synthesis of Molnupiravir. 202121005152A. IN Patent. 2021 August 20;</Citation>
        </Reference>
        <Reference>
          <Citation>Reddy D.R.S., Reddy P.S., Rao G.V.G. Improved Process for Molnupiravir. 202141011933A. IN Patent. 2021 July 23;</Citation>
        </Reference>
        <Reference>
          <Citation>Schooley R.T., Carlin A.F., Beadle J.R., Valiaeva N., Zhang X.Q., Clark A.E., McMillan R.E., Leibel S.L., McVicar R.N., Xie J., et al.  Rethinking remdesivir: Synthesis, antiviral activity and pharmacokinetics of oral lipid prodrugs. Antimicrob. Agents Chemother. 2021:AAC0115521. doi: 10.1101/2020.08.26.269159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.08.26.269159</ArticleId>
            <ArticleId IdType="pmc">PMC8448143</ArticleId>
            <ArticleId IdType="pubmed">34310217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation> [(accessed on 12 August 2021)].  Available online:  https://www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19/</Citation>
        </Reference>
        <Reference>
          <Citation>.  An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19. JAMA. 2021;325:880–881. doi: 10.1001/jama.2020.24415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.24415</ArticleId>
            <ArticleId IdType="pubmed">33306087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavan M., Bolcato G., Bassani D., Sturlese M., Moro S. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J. Enzyme Inhib. Med. Chem. 2021;36:1646–1650. doi: 10.1080/14756366.2021.1954919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14756366.2021.1954919</ArticleId>
            <ArticleId IdType="pmc">PMC8300928</ArticleId>
            <ArticleId IdType="pubmed">34289752</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
